Health
Results: 73-84 of 8661

Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

ASTRAZENECA’S IMFINZI (DURVALUMAB) RECOMMENDED BY NICE FOLLOWING MHRA APPROVAL AS FIRST IMMUNOTHERAPY IN COMBINATION WITH PERIOPERATIVE CHEMOTHERAPY IN RESECTABLE GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER

GenesisCare and SeeTreat to bring personalised Offline Adaptive Monitoring to more than 40 radiation oncology centres across Australia

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma






